Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids
Background PARP inhibitors (PARPis) are new targeted agents that exploit homologous recombination DNA repair deficiencies (HRDs), which are present in 50% of high-grade serous carcinoma (HGSC) cases. Currently, olaparib is approved as maintenance therapy for BRCA1/2-mutated HGSC, and niraparib is ap...
Shranjeno v:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis Group
2026-12-01
|
| Serija: | Cancer Biology & Therapy |
| Teme: | |
| Online dostop: | https://www.tandfonline.com/doi/10.1080/15384047.2025.2611602 |
| Oznake: |
Brez oznak, prvi označite!
|